Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression

Roberto Ferrarese, Griffith R. Harsh IV, Ajay K. Yadav, Eva Bug, Daniel Maticzka, Wilfried Reichardt, Stephen M. Dombrowski, Tyler E. Miller, Anie P. Masilamani, Fangping Dai, Hyunsoo Kim, Michael Hadler, Denise M Scholtens, Irene L.Y. Yu, Jürgen Beck, Vinodh Srinivasasainagendra, Fabrizio Costa, Nicoleta Baxan, Dietmar Pfeifer, Dominik Von ElverfeldtRolf Backofen, Astrid Weyerbrock, Christine W. Duarte, Xiaolin He, Marco Prinz, James P Chandler, Hannes Vogel, Arnab Chakravarti, Jeremy N. Rich, Maria S. Carro*, Markus Bredel

*Corresponding author for this work

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Tissue-specific alternative splicing is critical for the emergence of tissue identity during development, yet the role of this process in malignant transformation is undefined. Tissue-specific splicing involves evolutionarily conserved, alternative exons that represent only a minority of the total alternative exons identified. Many of these conserved exons have functional features that influence signaling pathways to profound biological effect. Here, we determined that lineage-specific splicing of a brain-enriched cassette exon in the membrane-binding tumor suppressor annexin A7 (ANXA7) diminishes endosomal targeting of the EGFR oncoprotein, consequently enhancing EGFR signaling during brain tumor progression. ANXA7 exon splicing was mediated by the ribonucleoprotein PTBP1, which is normally repressed during neuronal development. PTBP1 was highly expressed in glioblastomas due to loss of a brain-enriched microRNA (miR-124) and to PTBP1 amplification. The alternative ANXA7 splicing trait was present in precursor cells, suggesting that glioblastoma cells inherit the trait from a potential tumor-initiating ancestor and that these cells exploit this trait through accumulation of mutations that enhance EGFR signaling. Our data illustrate that lineage-specific splicing of a tissue-regulated alternative exon in a constituent of an oncogenic pathway eliminates tumor suppressor functions and promotes glioblastoma progression. This paradigm may offer a general model as to how tissue-specific regulatory mechanisms can reprogram normal developmental processes into oncogenic ones.

Original languageEnglish (US)
Pages (from-to)2861-2876
Number of pages16
JournalJournal of Clinical Investigation
Volume124
Issue number7
DOIs
StatePublished - Jul 1 2014

Fingerprint

Glioblastoma
Exons
Annexin A7
Brain
Annexins
Ribonucleoproteins
Neoplastic Stem Cells
Oncogene Proteins
Alternative Splicing
MicroRNAs
Brain Neoplasms
Neoplasms
Membranes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ferrarese, R., Harsh IV, G. R., Yadav, A. K., Bug, E., Maticzka, D., Reichardt, W., ... Bredel, M. (2014). Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. Journal of Clinical Investigation, 124(7), 2861-2876. https://doi.org/10.1172/JCI68836
Ferrarese, Roberto ; Harsh IV, Griffith R. ; Yadav, Ajay K. ; Bug, Eva ; Maticzka, Daniel ; Reichardt, Wilfried ; Dombrowski, Stephen M. ; Miller, Tyler E. ; Masilamani, Anie P. ; Dai, Fangping ; Kim, Hyunsoo ; Hadler, Michael ; Scholtens, Denise M ; Yu, Irene L.Y. ; Beck, Jürgen ; Srinivasasainagendra, Vinodh ; Costa, Fabrizio ; Baxan, Nicoleta ; Pfeifer, Dietmar ; Von Elverfeldt, Dominik ; Backofen, Rolf ; Weyerbrock, Astrid ; Duarte, Christine W. ; He, Xiaolin ; Prinz, Marco ; Chandler, James P ; Vogel, Hannes ; Chakravarti, Arnab ; Rich, Jeremy N. ; Carro, Maria S. ; Bredel, Markus. / Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 7. pp. 2861-2876.
@article{3314329e50d34de8b3cedfb69757cf5c,
title = "Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression",
abstract = "Tissue-specific alternative splicing is critical for the emergence of tissue identity during development, yet the role of this process in malignant transformation is undefined. Tissue-specific splicing involves evolutionarily conserved, alternative exons that represent only a minority of the total alternative exons identified. Many of these conserved exons have functional features that influence signaling pathways to profound biological effect. Here, we determined that lineage-specific splicing of a brain-enriched cassette exon in the membrane-binding tumor suppressor annexin A7 (ANXA7) diminishes endosomal targeting of the EGFR oncoprotein, consequently enhancing EGFR signaling during brain tumor progression. ANXA7 exon splicing was mediated by the ribonucleoprotein PTBP1, which is normally repressed during neuronal development. PTBP1 was highly expressed in glioblastomas due to loss of a brain-enriched microRNA (miR-124) and to PTBP1 amplification. The alternative ANXA7 splicing trait was present in precursor cells, suggesting that glioblastoma cells inherit the trait from a potential tumor-initiating ancestor and that these cells exploit this trait through accumulation of mutations that enhance EGFR signaling. Our data illustrate that lineage-specific splicing of a tissue-regulated alternative exon in a constituent of an oncogenic pathway eliminates tumor suppressor functions and promotes glioblastoma progression. This paradigm may offer a general model as to how tissue-specific regulatory mechanisms can reprogram normal developmental processes into oncogenic ones.",
author = "Roberto Ferrarese and {Harsh IV}, {Griffith R.} and Yadav, {Ajay K.} and Eva Bug and Daniel Maticzka and Wilfried Reichardt and Dombrowski, {Stephen M.} and Miller, {Tyler E.} and Masilamani, {Anie P.} and Fangping Dai and Hyunsoo Kim and Michael Hadler and Scholtens, {Denise M} and Yu, {Irene L.Y.} and J{\"u}rgen Beck and Vinodh Srinivasasainagendra and Fabrizio Costa and Nicoleta Baxan and Dietmar Pfeifer and {Von Elverfeldt}, Dominik and Rolf Backofen and Astrid Weyerbrock and Duarte, {Christine W.} and Xiaolin He and Marco Prinz and Chandler, {James P} and Hannes Vogel and Arnab Chakravarti and Rich, {Jeremy N.} and Carro, {Maria S.} and Markus Bredel",
year = "2014",
month = "7",
day = "1",
doi = "10.1172/JCI68836",
language = "English (US)",
volume = "124",
pages = "2861--2876",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

Ferrarese, R, Harsh IV, GR, Yadav, AK, Bug, E, Maticzka, D, Reichardt, W, Dombrowski, SM, Miller, TE, Masilamani, AP, Dai, F, Kim, H, Hadler, M, Scholtens, DM, Yu, ILY, Beck, J, Srinivasasainagendra, V, Costa, F, Baxan, N, Pfeifer, D, Von Elverfeldt, D, Backofen, R, Weyerbrock, A, Duarte, CW, He, X, Prinz, M, Chandler, JP, Vogel, H, Chakravarti, A, Rich, JN, Carro, MS & Bredel, M 2014, 'Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression', Journal of Clinical Investigation, vol. 124, no. 7, pp. 2861-2876. https://doi.org/10.1172/JCI68836

Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. / Ferrarese, Roberto; Harsh IV, Griffith R.; Yadav, Ajay K.; Bug, Eva; Maticzka, Daniel; Reichardt, Wilfried; Dombrowski, Stephen M.; Miller, Tyler E.; Masilamani, Anie P.; Dai, Fangping; Kim, Hyunsoo; Hadler, Michael; Scholtens, Denise M; Yu, Irene L.Y.; Beck, Jürgen; Srinivasasainagendra, Vinodh; Costa, Fabrizio; Baxan, Nicoleta; Pfeifer, Dietmar; Von Elverfeldt, Dominik; Backofen, Rolf; Weyerbrock, Astrid; Duarte, Christine W.; He, Xiaolin; Prinz, Marco; Chandler, James P; Vogel, Hannes; Chakravarti, Arnab; Rich, Jeremy N.; Carro, Maria S.; Bredel, Markus.

In: Journal of Clinical Investigation, Vol. 124, No. 7, 01.07.2014, p. 2861-2876.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression

AU - Ferrarese, Roberto

AU - Harsh IV, Griffith R.

AU - Yadav, Ajay K.

AU - Bug, Eva

AU - Maticzka, Daniel

AU - Reichardt, Wilfried

AU - Dombrowski, Stephen M.

AU - Miller, Tyler E.

AU - Masilamani, Anie P.

AU - Dai, Fangping

AU - Kim, Hyunsoo

AU - Hadler, Michael

AU - Scholtens, Denise M

AU - Yu, Irene L.Y.

AU - Beck, Jürgen

AU - Srinivasasainagendra, Vinodh

AU - Costa, Fabrizio

AU - Baxan, Nicoleta

AU - Pfeifer, Dietmar

AU - Von Elverfeldt, Dominik

AU - Backofen, Rolf

AU - Weyerbrock, Astrid

AU - Duarte, Christine W.

AU - He, Xiaolin

AU - Prinz, Marco

AU - Chandler, James P

AU - Vogel, Hannes

AU - Chakravarti, Arnab

AU - Rich, Jeremy N.

AU - Carro, Maria S.

AU - Bredel, Markus

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Tissue-specific alternative splicing is critical for the emergence of tissue identity during development, yet the role of this process in malignant transformation is undefined. Tissue-specific splicing involves evolutionarily conserved, alternative exons that represent only a minority of the total alternative exons identified. Many of these conserved exons have functional features that influence signaling pathways to profound biological effect. Here, we determined that lineage-specific splicing of a brain-enriched cassette exon in the membrane-binding tumor suppressor annexin A7 (ANXA7) diminishes endosomal targeting of the EGFR oncoprotein, consequently enhancing EGFR signaling during brain tumor progression. ANXA7 exon splicing was mediated by the ribonucleoprotein PTBP1, which is normally repressed during neuronal development. PTBP1 was highly expressed in glioblastomas due to loss of a brain-enriched microRNA (miR-124) and to PTBP1 amplification. The alternative ANXA7 splicing trait was present in precursor cells, suggesting that glioblastoma cells inherit the trait from a potential tumor-initiating ancestor and that these cells exploit this trait through accumulation of mutations that enhance EGFR signaling. Our data illustrate that lineage-specific splicing of a tissue-regulated alternative exon in a constituent of an oncogenic pathway eliminates tumor suppressor functions and promotes glioblastoma progression. This paradigm may offer a general model as to how tissue-specific regulatory mechanisms can reprogram normal developmental processes into oncogenic ones.

AB - Tissue-specific alternative splicing is critical for the emergence of tissue identity during development, yet the role of this process in malignant transformation is undefined. Tissue-specific splicing involves evolutionarily conserved, alternative exons that represent only a minority of the total alternative exons identified. Many of these conserved exons have functional features that influence signaling pathways to profound biological effect. Here, we determined that lineage-specific splicing of a brain-enriched cassette exon in the membrane-binding tumor suppressor annexin A7 (ANXA7) diminishes endosomal targeting of the EGFR oncoprotein, consequently enhancing EGFR signaling during brain tumor progression. ANXA7 exon splicing was mediated by the ribonucleoprotein PTBP1, which is normally repressed during neuronal development. PTBP1 was highly expressed in glioblastomas due to loss of a brain-enriched microRNA (miR-124) and to PTBP1 amplification. The alternative ANXA7 splicing trait was present in precursor cells, suggesting that glioblastoma cells inherit the trait from a potential tumor-initiating ancestor and that these cells exploit this trait through accumulation of mutations that enhance EGFR signaling. Our data illustrate that lineage-specific splicing of a tissue-regulated alternative exon in a constituent of an oncogenic pathway eliminates tumor suppressor functions and promotes glioblastoma progression. This paradigm may offer a general model as to how tissue-specific regulatory mechanisms can reprogram normal developmental processes into oncogenic ones.

UR - http://www.scopus.com/inward/record.url?scp=84903778038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903778038&partnerID=8YFLogxK

U2 - 10.1172/JCI68836

DO - 10.1172/JCI68836

M3 - Article

C2 - 24865424

AN - SCOPUS:84903778038

VL - 124

SP - 2861

EP - 2876

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -